概述

  • 产品名称Anti-MARK 1+2+3+4抗体
    参阅全部 MARK 1+2+3+4 一抗
  • 描述
    兔多克隆抗体to MARK 1+2+3+4
  • 特异性ab74131 detects endogenous levels of total MARK 1+2+3+4 protein.
  • 经测试应用适用于: WB, ELISA, IHC-P, ICC/IFmore details
  • 种属反应性
    与反应: Mouse, Human
    预测可用于: Rat
  • 免疫原

    Synthetic non-phosphopeptide derived from human MARK1/2/3/4 around the phosphorylation site of threonine 215 (L-D-TP-F-C).

  • 阳性对照
    • Human breast carcinoma tissue. Extracts from COS-7 cells. HeLa cells.

性能

应用

Our Abpromise guarantee covers the use of ab74131 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
WB 1/500 - 1/1000. Predicted molecular weight: 89 kDa.
ELISA 1/5000.
IHC-P 1/50 - 1/100.
ICC/IF 1/100 - 1/500.

靶标

Anti-MARK 1+2+3+4 antibody 图像

  • All lanes : Anti-MARK 1+2+3+4 antibody (ab74131) at 1/500 dilution

    Lane 1 : Extracts from COS-7 cells
    Lane 2 : Extracts from COS-7 cells with immunising peptide at 5 µg

    Lysates/proteins at 5 µg per lane.


    Predicted band size : 89 kDa
    Observed band size : 89 kDa
  • Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ab74131, at 1/50 dilution, in the presence (right panel) or absence (left panel) of immunising peptide.
  • Immunofluorescence analysis of HeLa cells, using ab74131 at 1/100 dilution, in the presence (right panel) or absence (left panel) of immunising peptide.

Anti-MARK 1+2+3+4 antibody (ab74131)参考文献

This product has been referenced in:
  • Mian I  et al. LKB1 destabilizes microtubules in myoblasts and contributes to myoblast differentiation. PLoS One 7:e31583 (2012). WB ; Mouse . Read more (PubMed: 22348111) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab74131.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"